Modality
Peptide
MOA
AuroraAi
Target
TYK2
Pathway
Checkpoint
MelanomaMigraine
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
Sep 2018
→ Jul 2030
Phase 3Current
NCT06384213
175 pts·Migraine
2021-01→2030-07·Terminated
NCT07090804
22 pts·Melanoma
2021-03→2026-06·Not yet recruiting
NCT07902060
711 pts·Melanoma
2018-09→TBD·Not yet recruiting
908 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-122mo awayPh3 Readout· Melanoma
2030-07-204.3y awayPh3 Readout· Migraine
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Not yet…
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2026-06-12 · 2mo away
Melanoma
Ph3 Readout
2030-07-20 · 4.3y away
Migraine
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06384213 | Phase 3 | Migraine | Terminated | 175 | PFS |
| NCT07090804 | Phase 3 | Melanoma | Not yet recr... | 22 | PANSS |
| NCT07902060 | Phase 3 | Melanoma | Not yet recr... | 711 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |